Calretinin ELISA Assay Kit


The Eagle Biosciences Calretinin ELISA Assay Kit is used for the quantitative determination of Calretinin in human serum and EDTA plasma. The Calretinin ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

Calretinin ELISA Assay Kit

For Research Use Only

Size: 1×96 wells
Sensitivity: 0.05 ng/mL
Dynamic Range: 0.25- 4.0 ng/mL
Incubation Time: 4.5 hours
Sample Type: EDTA Plasma, Serum
Sample Size: 15 µl

Product manufactured in Germany by DLD Diagnostika

Additional Information

Assay Background

Two Million tons of asbestos are still being manufactured annually. Over 100,000 people die each year from cancer diseases caused by exposure to asbestos. The most common types of asbestos-related cancer diseases are malignant lung tumors and pleural mesothelioma. Asbestos-associated cancers remain on a high level. Blood-based markers are urgently needed to limit invasive diagnostic procedures. Calretinin levels are significantly increased in malignant mesothelioma according to recent studies. The Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA) and DLD Diagnostika have developed a new Sandwich ELISA for the early detection of human calretinin and is distributed by Eagle Biosciences.

Assay Principle

The microtiter plate of the Calretinin ELISA is coated with a capture antibody. The diluted sample is added, and any antigen present binds to capture antibody. After a washing step the detecting antibody (biotinylated anti-calretinin antibody) is added and binds to antigen. After another washing step the enzyme conjugate streptavidin-peroxidase is added and binds to detecting antibody. The following substrate TMB / peroxidase reaction is monitored at 450 nm (reference wavelength at 620 nm).

Typical Standard Curve



Product Manual



  • Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, Kollmeier J, Scherpereel A, Brüning T, Johnen G. Development of an enzymelinked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10:242
  • Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 2014; 1844: 874-883
  • Calretinin ELISA: A New Assay for the Detection of Mesothelioma in Blood Samples. Georg Johnen, Irina Raiko, Ingrid Sander, Daniel G. Weber, Monika Raulf-Heimsoth, Adrian Gillissen, Jens Kollmeier, Klaus- Michael Müller, Arnaud Scherpereel, Thomas Brüning
  • Johen G., Gawrych K., Casjens S., Pesch B., Weber D.G., Taeger D., Lehnert M., Kollmeier J., Bauer T., Musk A., Robinson B.W.S., Brüning T., Creaney J. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer 2017; 17:386.
  • Casjens S, Weber DG, Johnrn G, et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population based cohort study. BML Open 2017;7e017104.doi:10.1136/bmjopen-2017-017104
  • Raiko I., Sander I., Weber D.G., et al. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10:242